Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Leukemia Therapeutics Treatment Market Outlook for 2023 to 2033

The leukemia therapeutics treatment market valuation is US$ 15,246.7 million in 2023. In 2022, the value was US$ 14,504.8 million. The market is predicted to grow at a healthy CAGR of 7.1% from 2023 to 2033. The valuation of the leukemia therapeutics treatment market is anticipated to reach US$ 30,318.5 million by 2033.

Production Analysis of the Leukemia Therapeutics Treatment Market

  • The number of patients afflicted by leukemia is increasing around the world. Thus, leukemia therapeutics treatment is seeing a rise in demand.
  • To cope with the rising cases of leukemia around the world, companies in the market are innovating new drugs and treatments that are more effective.
  • Companies in the market are relying on technology to enhance treatment outcomes. With the help of technology, companies can introduce new medicines and make scientific breakthroughs in treatment.
  • People are becoming increasingly aware of the need for preventive healthcare. With the aid of preventive healthcare, leukemia can be detected early. Thus, more time can be invested into leukemia treatment.
  • Side effects associated with leukemia treatment, including bruising, ulcers, and diarrhea, are restraining factors for the leukemia therapeutics treatment market. However, the benefits of leukemia treatment are apparent to consumers, and thus, there is a willingness to undertake it despite the side effects.
Attributes Details
Leukemia Therapeutics Treatment Market Value for 2023 US$ 15,246.7 million
Projected Market Value for 2033 US$ 30,318.5 million
Value-based CAGR of Market for 2023 to 2033 7.1%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Historical Performance of the Leukemia Therapeutics Treatment Market

The leukemia therapeutics treatment market was valued at US$ 12034.0 million in 2017. The market progressed at a sluggish CAGR of 3.8% over the historical period from 2017 to 2022.

Due to the pandemic, an increasing number of resources were diverted towards Covid-19 treatment. As a result, leukemia therapeutics treatment suffered during the historical period. Nonetheless, the progress in different types of treatment and medicines continued. At the end of the historical period in 2022, the value of the leukemia therapeutics treatment market had reached US$ 14,504.8 million.

Market Value (2017) US$ 12,034.0 million
Historical CAGR (2017 to 2022) 3.8%
Historical Market Valuation (2022) US$ 14,504.8 million

Long-Term Analysis of the Leukemia Therapeutics Treatment Market

The leukemia therapeutics treatment market is estimated to be US$ 15,246.7 million in size in 2023. The progress of the market is predicted to be promising, with a CAGR of 7.1% over the forecast period.

The progress in the forecast period is set to outpace the progress in the historical period. As companies keep innovating with the help of technology, leukemia treatment is getting more effective. The cases of leukemia are also not slated to slow down over the forecast period, necessitating treatment for the disease.

Medical care is increasingly looked upon positively. Thus, leukemia therapeutics treatment is widely accepted to combat the disease. By 2033, the valuation of the leukemia therapeutics treatment market is expected to be US$ 30,318.5 million.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Leukemia Therapeutics Treatment Market Trends

  • Government campaigns all over the world are aiding the leukemia therapeutics treatment industry. The campaigns raise awareness about cancer, including leukemia, and encourage people to seek treatment.
  • The emerging efficiency of imaging scans like CT scans and MRI is set to impact the leukemia therapeutics treatment industry positively.
  • As more people seek chemotherapy for cancer treatment, the procedure is gaining increasing acceptance. Chemotherapy as part of leukemia treatment is thus anticipated to grow positively.
  • Companies in the leukemia therapeutics treatment market are concentrating on scientific breakthroughs in the treatment. By delivering breakthroughs, companies can keep innovating and making treatment more effective.
  • Innovations and breakthroughs require significant investment in technology. Players in the leukemia therapeutics treatment market are thus seeking funding. Funding is coming from both public and private sources.
  • Due to breakthroughs in treatment, the survival rates for leukemia are growing. Thus, the image of the leukemia therapeutics treatment market is being affected positively.
  • Commonly, Leukemia affects people 65 years or older. However, acute lymphocytic leukemia (ALL) is most commonly seen in persons 20 years or younger. The two age groups represent a significant consumer base for the leukemia therapeutics treatment industry.

Comparative View of Adjacent Markets

In addition to the leukemia therapeutics treatment market, reports on two adjacent markets, namely the venous ulcer treatment market and the large granular lymphocytic leukemia (LGLL) therapeutics market, have been discussed in the section below.

The trends in various treatment markets can be observed by looking at the markets in conjunction. The positive trajectories of healthcare treatment markets can also be observed.

Leukemia Therapeutics Treatment Market:

Value-based CAGR (2023 to 2033) 7.1%
Projected Market Value (2033) US$ 30,318.5 million
Market Trends
  • Government campaigns advertising the benefits of leukemia treatment
  • Increasing survival rates boosting the market
Restraints
  • Side effects associated with treatment
Growth Factors
  • Increase in the number of patients affected by leukemia
  • Innovations and breakthroughs with the aid of technology

Venous Ulcer Treatment Market:

Value-based CAGR (2023 to 2033) 6.5%
Projected Market Value (2033) US$ 7.61 billion
Market Trends
  • Compression therapy reduces the time required for treatment
  • Innovations such as multi-component and two-layer compression therapy solutions
Restraints
  • Lack of knowledge among people about treatment
Growth Factors
  • Venous ulcers affecting a large number of people
  • Research and development slated to unlock new opportunities

Large Granular Lymphocytic Leukemia (LGLL) Therapeutic Market:

Value-based CAGR (2023 to 2033) 16.03%
Projected Market Value (2033) US$ 12,700 million
Market Trends
  • Clinical trials increasing in number
  • Heavy investment in companies
Growth Factors
  • Rise in adoption of natural killer cells
  • New therapies and drugs promise a bright future for the market

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Outlook

The leukemia therapeutics treatment market can be divided into four segments: treatment, molecule, mode of administration, and indication. By looking at the segments, the inclinations of the consumers become clear. The types of treatment and the way the consumers choose to receive treatment can also be seen.

Consumers Prefer Targeted Drugs & Immunotherapy for Leukemia Treatment

Targeted drugs & immunotherapy are the preferred mode of treatment for patients. In 2022, targeted drugs & immunotherapy accounted for 57.2% of the market share by treatment.

Several drugs, such as Gleevec, Bosulif, and Sprycel, are in the leukemia treatment market. Many drugs are also under trial, with the Revumenib drug showing positive results while testing. Thus, drugs and immunotherapy are popular treatments. Chemotherapy is the preferred treatment method highly sought by patients in increasing numbers.

Attributes Details
Top Treatment Targeted Drugs & Immunotherapy
Market Share in 2022 57.2%

Use of Small Molecules in the Treatment Owing to their Effectiveness

Small molecules are the most commonly used type of molecule in leukemia therapeutics treatment. In 2022, small molecules accounted for 55.6% of the market share by molecule.

The adoption of small molecules through inhibitors has been effective in leukemia treatment. Further, small molecule treatment has also led to fewer side effects in patients.

Attributes Details
Top Molecule Small Molecule
Market Share in 2022 55.6%

Injectables Lead the Leukemia Treatment Market by Mode of Drug Administration

Injecting drugs is the preferred mode of administration for patients. In 2022, injectable treatment accounted for 61.7% of the market share by mode of administration.

Injections are commonly believed to act faster than doses of oral medicine. In leukemia treatment, consumers also opt for injectables as a mode for faster results.

Attributes Details
Top Mode of Administration Injectable
Market Share in 2022 61.7%

Chronic Myeloid Leukemia (CML) is the Most Common Type of Leukemia for Which Treatment is Sought

Chronic myeloid leukemia patients (CML) are the leading leukemia therapeutics treatment market. In 2022, the CML contributed to 43.2% of the market share by indication.
Effective CML treatment has drastically improved the survival rate. About 90% of the patients of CML are now expected to pull through the disease. Thus, the treatment of CML has earned an enhanced reputation.

Attributes Details
Top Indication Chronic Myeloid Leukemia (CML)
Market Share in 2022 43.2%

Country-Wise Analysis

North America and Europe account for a large share of the market. In 2022, North America and Europe contributed 37.6% and 25.6% of the market share, respectively. The United States, in particular, held 33.3% of the global market share.

Countries in the Asia Pacific, like China, India, Japan, and South Korea, are slated to show substantial growth in the market over the coming years. Rapidly increasing population and economic development are leading factors in the growth of the market in the Asia Pacific region.

Countries CAGR
South Korea 10.0%
China 10.6%
Japan 9.6%
India 8.6%
Australia 6.9%

Focus on Innovation and Advanced Treatment Procedures in China

China is predicted to show incredible growth in the leukemia therapeutics treatment market during the forecast period. The Chinese market is expected to grow at a stellar CAGR of 10.6% through 2033.

Players in the Chinese market are increasingly focused on breakthroughs. Therefore, the nature of leukemia treatment in China is getting modernized. For example, in January 2022, Chinese scientists found a potential treatment for leukemia with the infusion of nanoparticles into the bloodstream.

Top-notch Cancer Care Facilities Facilitate Growth of the Market in South Korea

South Korea is another Asian country with significant potential for the market. The South Korean market is forecasted to grow at an impressive CAGR of 10.0% over the forecast period.

Impressive healthcare facilities in South Korea attract even people from outside the country. Cancer treatment and research are also on the up in South Korea. Some expenses of cancer treatment are reimbursable in the country. Thus, the market is well-positioned in South Korea.

Aging Demographics in Japan Drives Leukemia Therapeutics Treatment

The market is expected to thrive in Japan as well. The Japanese market is expected to grow at a sturdy CAGR of 9.6% through 2033.

The average age in Japan is rising rapidly. Elderly people are prone to leukemia and form a huge section of the customer base for the leukemia therapeutics treatment industry. Therefore, Japan is rife with opportunities for the market.

Competitive Landscape in the Leukemia Therapeutics Treatment Market

Heavy investment is needed for innovations and breakthroughs in leukemia treatment. Thus, large companies with financial capacity hold a strong position in the market. However, with the aid of government and private funding, operations on a smaller scale also have scope.

Companies in the market have to wait for approvals to launch products into the market. Nonetheless, the players in the market are focused on having a wide range of products to treat different types of leukemia.

Recent Developments in the Leukemia Therapeutics Treatment Market

  • In October 2023, Syndax Pharmaceuticals announced that Revumenib had met its goals in the trial. The pathway could thus be cleared for the launch of the drug in the market.
  • In October 2023, Moleculin Biotech started a trial for a treatment that combines annamycin and cytarabine. The treatment is designed with acute myeloid leukemia (AML) patients in mind.
  • In November 2022, BeiGene’s drug Burkina (zanubrutinib) received approval from the European Council. The drug is aimed at patients with chronic lymphocytic leukemia (CLL).
  • In September 2020, Bristol Myers Squibb’s Onureg drug was approved by the US Food and Drug Administration (FDA). Patients who are in remission are the targeted consumers of the drug.

Key Companies in the Leukemia Therapeutics Treatment Market

  • Ambit Biosciences Corporation
  • Biogen Idec, Inc.
  • Ariad Pharmaceuticals, Inc.
  • Bristol-Myers Squibb
  • Novartis Pharmaceuticals
  • Pfizer
  • Others

Key Segments

By Treatment:

  • Targeted Drugs & Immunotherapy
  • Chemotherapy

By Molecule:

  • Biologics
  • Single Molecule

By Mode of Administration:

  • Injectable
  • Oral

By Indication:

  • AML
  • CML
  • ALL
  • CLL

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

How Big is the Leukemia Therapeutics Treatment Market?

The leukemia therapeutics treatment market valuation is US$ 15,246.7 million in 2023.

What Will be the Size of the Leukemia Therapeutics Treatment Market by 2033?

The market size of leukemia therapeutics treatment is predicted to reach US$ 30,318.5 million by 2033.

Why is the Demand for Leukemia Therapeutics Treatment Increasing?

Increasing cases of leukemia and a rise in the global aging population are stimulating the market demand.

How will the Leukemia Therapeutics Treatment Market Progress?

The leukemia therapeutics treatment market is expected to progress at a CAGR of 7.1% from 2023 to 2033.

Who are the Prominent Companies in the Leukemia Therapeutics Treatment Market?

Ambit Biosciences Corporation, Biogen Idec, Inc., Ariad Pharmaceuticals, Inc., and Bristol-Myers Squibb are some of the prominent companies in the market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market

4. Global Industry Analysis and Outlook 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033

        5.3.1. Targeted Drugs

        5.3.2. Chemotherapy

    5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033

6. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Molecule Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Molecule Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Molecule Type, 2023 to 2033

        6.3.1. Biologics

        6.3.2. Small Molecules

    6.4. Y-o-Y Growth Trend Analysis By Molecule Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Molecule Type, 2023 to 2033

7. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Mode of Administration, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Mode of Administration, 2023 to 2033

        7.3.1. Injectable

        7.3.2. Oral

    7.4. Y-o-Y Growth Trend Analysis By Mode of Administration, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Mode of Administration, 2023 to 2033

8. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        8.3.1. AML

        8.3.2. CML

        8.3.3. ALL

        8.3.4. CLL

    8.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

9. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Western Europe

        9.3.4. Eastern Europe

        9.3.5. South Asia and Pacific

        9.3.6. East Asia

        9.3.7. Middle East and Africa

    9.4. Market Attractiveness Analysis By Region

10. North America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. The USA

            10.2.1.2. Canada

        10.2.2. By Treatment Type

        10.2.3. By Molecule Type

        10.2.4. By Mode of Administration

        10.2.5. By Type

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment Type

        10.3.3. By Molecule Type

        10.3.4. By Mode of Administration

        10.3.5. By Type

    10.4. Key Takeaways

11. Latin America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Treatment Type

        11.2.3. By Molecule Type

        11.2.4. By Mode of Administration

        11.2.5. By Type

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment Type

        11.3.3. By Molecule Type

        11.3.4. By Mode of Administration

        11.3.5. By Type

    11.4. Key Takeaways

12. Western Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. United Kingdom

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Western Europe

        12.2.2. By Treatment Type

        12.2.3. By Molecule Type

        12.2.4. By Mode of Administration

        12.2.5. By Type

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment Type

        12.3.3. By Molecule Type

        12.3.4. By Mode of Administration

        12.3.5. By Type

    12.4. Key Takeaways

13. Eastern Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Poland

            13.2.1.2. Russia

            13.2.1.3. Czech Republic

            13.2.1.4. Romania

            13.2.1.5. Rest of Eastern Europe

        13.2.2. By Treatment Type

        13.2.3. By Molecule Type

        13.2.4. By Mode of Administration

        13.2.5. By Type

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment Type

        13.3.3. By Molecule Type

        13.3.4. By Mode of Administration

        13.3.5. By Type

    13.4. Key Takeaways

14. South Asia and Pacific Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Bangladesh

            14.2.1.3. Australia

            14.2.1.4. New Zealand

            14.2.1.5. Rest of South Asia and Pacific

        14.2.2. By Treatment Type

        14.2.3. By Molecule Type

        14.2.4. By Mode of Administration

        14.2.5. By Type

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment Type

        14.3.3. By Molecule Type

        14.3.4. By Mode of Administration

        14.3.5. By Type

    14.4. Key Takeaways

15. East Asia Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. China

            15.2.1.2. Japan

            15.2.1.3. South Korea

        15.2.2. By Treatment Type

        15.2.3. By Molecule Type

        15.2.4. By Mode of Administration

        15.2.5. By Type

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Treatment Type

        15.3.3. By Molecule Type

        15.3.4. By Mode of Administration

        15.3.5. By Type

    15.4. Key Takeaways

16. Middle East and Africa Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Treatment Type

        16.2.3. By Molecule Type

        16.2.4. By Mode of Administration

        16.2.5. By Type

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Treatment Type

        16.3.3. By Molecule Type

        16.3.4. By Mode of Administration

        16.3.5. By Type

    16.4. Key Takeaways

17. Key Countries Industry Analysis and Outlook

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Treatment Type

            17.1.2.2. By Molecule Type

            17.1.2.3. By Mode of Administration

            17.1.2.4. By Type

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Treatment Type

            17.2.2.2. By Molecule Type

            17.2.2.3. By Mode of Administration

            17.2.2.4. By Type

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Treatment Type

            17.3.2.2. By Molecule Type

            17.3.2.3. By Mode of Administration

            17.3.2.4. By Type

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Treatment Type

            17.4.2.2. By Molecule Type

            17.4.2.3. By Mode of Administration

            17.4.2.4. By Type

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Treatment Type

            17.5.2.2. By Molecule Type

            17.5.2.3. By Mode of Administration

            17.5.2.4. By Type

    17.6. United Kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Treatment Type

            17.6.2.2. By Molecule Type

            17.6.2.3. By Mode of Administration

            17.6.2.4. By Type

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Treatment Type

            17.7.2.2. By Molecule Type

            17.7.2.3. By Mode of Administration

            17.7.2.4. By Type

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Treatment Type

            17.8.2.2. By Molecule Type

            17.8.2.3. By Mode of Administration

            17.8.2.4. By Type

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Treatment Type

            17.9.2.2. By Molecule Type

            17.9.2.3. By Mode of Administration

            17.9.2.4. By Type

    17.10. Poland

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Treatment Type

            17.10.2.2. By Molecule Type

            17.10.2.3. By Mode of Administration

            17.10.2.4. By Type

    17.11. Russia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Treatment Type

            17.11.2.2. By Molecule Type

            17.11.2.3. By Mode of Administration

            17.11.2.4. By Type

    17.12. Czech Republic

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Treatment Type

            17.12.2.2. By Molecule Type

            17.12.2.3. By Mode of Administration

            17.12.2.4. By Type

    17.13. Romania

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Treatment Type

            17.13.2.2. By Molecule Type

            17.13.2.3. By Mode of Administration

            17.13.2.4. By Type

    17.14. India

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Treatment Type

            17.14.2.2. By Molecule Type

            17.14.2.3. By Mode of Administration

            17.14.2.4. By Type

    17.15. Bangladesh

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Treatment Type

            17.15.2.2. By Molecule Type

            17.15.2.3. By Mode of Administration

            17.15.2.4. By Type

    17.16. Australia

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Treatment Type

            17.16.2.2. By Molecule Type

            17.16.2.3. By Mode of Administration

            17.16.2.4. By Type

    17.17. New Zealand

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Treatment Type

            17.17.2.2. By Molecule Type

            17.17.2.3. By Mode of Administration

            17.17.2.4. By Type

    17.18. China

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Treatment Type

            17.18.2.2. By Molecule Type

            17.18.2.3. By Mode of Administration

            17.18.2.4. By Type

    17.19. Japan

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Treatment Type

            17.19.2.2. By Molecule Type

            17.19.2.3. By Mode of Administration

            17.19.2.4. By Type

    17.20. South Korea

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Treatment Type

            17.20.2.2. By Molecule Type

            17.20.2.3. By Mode of Administration

            17.20.2.4. By Type

    17.21. GCC Countries

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Treatment Type

            17.21.2.2. By Molecule Type

            17.21.2.3. By Mode of Administration

            17.21.2.4. By Type

    17.22. South Africa

        17.22.1. Pricing Analysis

        17.22.2. Market Share Analysis, 2022

            17.22.2.1. By Treatment Type

            17.22.2.2. By Molecule Type

            17.22.2.3. By Mode of Administration

            17.22.2.4. By Type

    17.23. Israel

        17.23.1. Pricing Analysis

        17.23.2. Market Share Analysis, 2022

            17.23.2.1. By Treatment Type

            17.23.2.2. By Molecule Type

            17.23.2.3. By Mode of Administration

            17.23.2.4. By Type

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Treatment Type

        18.3.3. By Molecule Type

        18.3.4. By Mode of Administration

        18.3.5. By Type

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Novartis International AG

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. GlaxoSmithKline Pharmaceuticals Limited

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Roche

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Bristol-Myers Squibb

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Genmab A/S

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Celgene Corporation

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Biogen

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Pfizer

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Ambit Biosciences Corporation

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Ariad Pharmaceuticals, Inc

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Autoimmune Disease Therapeutics Market

Published : July 2023

Explore Healthcare Insights

View Reports

Leukemia Therapeutics Treatment Market